A detailed history of Russell Investments Group, Ltd. transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Russell Investments Group, Ltd. holds 7,218 shares of ALDX stock, worth $34,790. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7,218
Holding current value
$34,790
% of portfolio
0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$3.19 - $6.32 $23,025 - $45,617
7,218 New
7,218 $38,000
Q3 2021

Nov 08, 2021

SELL
$7.94 - $11.31 $126,095 - $179,614
-15,881 Closed
0 $0
Q2 2021

Aug 04, 2021

BUY
$10.44 - $14.85 $165,797 - $235,832
15,881 New
15,881 $179,000
Q1 2021

May 10, 2021

SELL
$6.53 - $14.42 $305,617 - $674,884
-46,802 Closed
0 $0
Q4 2020

Feb 08, 2021

SELL
$6.31 - $8.13 $14,064 - $18,121
-2,229 Reduced 4.55%
46,802 $320,000
Q3 2020

Nov 09, 2020

BUY
$4.0 - $7.53 $27,308 - $51,407
6,827 Added 16.18%
49,031 $362,000
Q2 2020

Aug 05, 2020

SELL
$1.97 - $5.05 $18,624 - $47,742
-9,454 Reduced 18.3%
42,204 $175,000
Q4 2019

Jan 29, 2020

SELL
$4.73 - $7.98 $34,949 - $58,964
-7,389 Reduced 12.51%
51,658 $299,000
Q3 2019

Nov 01, 2019

SELL
$4.41 - $6.12 $313,992 - $435,744
-71,200 Reduced 54.67%
59,047 $313,000
Q1 2019

May 13, 2019

SELL
$7.14 - $9.85 $32,187 - $44,403
-4,508 Reduced 3.35%
130,247 $1.18 Million
Q4 2018

Feb 11, 2019

SELL
$7.26 - $13.29 $124,276 - $227,498
-17,118 Reduced 11.27%
134,755 $1.12 Million
Q3 2018

Oct 26, 2018

SELL
$6.8 - $14.35 $108,555 - $229,083
-15,964 Reduced 9.51%
151,873 $2.1 Million
Q2 2018

Aug 08, 2018

BUY
$6.95 - $9.18 $1.17 Million - $1.54 Million
167,837 New
167,837 $1.34 Million

Others Institutions Holding ALDX

About Aldeyra Therapeutics, Inc.


  • Ticker ALDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,323,100
  • Market Cap $281M
  • Description
  • Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...
More about ALDX
Track This Portfolio

Track Russell Investments Group, Ltd. Portfolio

Follow Russell Investments Group, Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Russell Investments Group, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Russell Investments Group, Ltd. with notifications on news.